Dyne Therapeutics (NASDAQ:DYN) Director Purchases $43,700.00 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Brian Posner acquired 2,500 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The shares were acquired at an average cost of $17.48 per share, with a total value of $43,700.00. Following the transaction, the director owned 22,500 shares in the company, valued at approximately $393,300. This trade represents a 12.50% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Dyne Therapeutics Stock Performance

Shares of Dyne Therapeutics stock opened at $17.04 on Monday. The company has a market capitalization of $2.82 billion, a P/E ratio of -5.29 and a beta of 1.09. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92. The company has a fifty day moving average of $18.28 and a 200 day moving average of $18.26. Dyne Therapeutics, Inc. has a fifty-two week low of $8.06 and a fifty-two week high of $25.00.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.04. During the same quarter in the prior year, the company posted ($1.05) earnings per share. On average, sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Perceptive Advisors LLC boosted its holdings in shares of Dyne Therapeutics by 34.2% during the 1st quarter. Perceptive Advisors LLC now owns 4,668,839 shares of the company’s stock valued at $84,646,000 after purchasing an additional 1,189,895 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Dyne Therapeutics by 63.5% during the 1st quarter. Bank of America Corp DE now owns 1,443,313 shares of the company’s stock valued at $26,167,000 after purchasing an additional 560,391 shares during the last quarter. California State Teachers Retirement System boosted its holdings in shares of Dyne Therapeutics by 15.6% during the 1st quarter. California State Teachers Retirement System now owns 139,663 shares of the company’s stock valued at $2,532,000 after purchasing an additional 18,863 shares during the last quarter. Royal Bank of Canada boosted its holdings in shares of Dyne Therapeutics by 267.6% during the 1st quarter. Royal Bank of Canada now owns 68,188 shares of the company’s stock valued at $1,236,000 after purchasing an additional 49,641 shares during the last quarter. Finally, Rock Springs Capital Management LP boosted its holdings in shares of Dyne Therapeutics by 6.5% during the 1st quarter. Rock Springs Capital Management LP now owns 972,198 shares of the company’s stock valued at $17,626,000 after purchasing an additional 59,243 shares during the last quarter. Institutional investors own 96.68% of the company’s stock.

Wall Street Analysts Forecast Growth

DYN has been the subject of several recent analyst reports. HC Wainwright dropped their target price on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, March 3rd. Jefferies Financial Group reaffirmed a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th. Morgan Stanley dropped their target price on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a report on Monday, March 2nd. Chardan Capital reaffirmed a “buy” rating and issued a $38.00 target price on shares of Dyne Therapeutics in a report on Monday, March 9th. Finally, Sanford C. Bernstein upped their target price on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. Three research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $35.00.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.